Leading edge: emerging drug, cell, and gene therapies for junctional epidermolysis bullosa.

Allison R KeithKirk TwaroskiChristen L EbensJakub Tolar

Published in: Expert opinion on biological therapy (2020)

Emerging therapies address the cutaneous symptoms of JEB but are unable to attend to systemic manifestations of the disease. Investigations into the molecular mechanism(s) underpinning the failure of systemic allogeneic cell therapies are necessary to expand the range of effective JEB therapies.

Keyphrases

single cell
cell therapy
stem cell transplantation
emergency department
gene expression
drug induced
mesenchymal stem cells